Matteo Levisetti
Chief Tech/Sci/R&D Officer bij CUE BIOPHARMA, INC.
Vermogen: 17 445 $ op 31-03-2024
Profiel
Matteo Levisetti's career history includes current and former positions as well as his education.
Currently, he is the Chief Medical Officer at Cue Biopharma, Inc. Prior to this, he held the position of Chief Medical Officer at DNAtrix, Inc. from 2019 to 2021.
Additionally, he served as the Executive Director-Clinical Development at Mirati Therapeutics, Inc. from 2016 to 2017 and as the Chief Medical Officer at Dauntless Pharmaceuticals, Inc. from 2017 to 2018.
He also worked as the Global Head & VP-Translational Medicine at Roche Pharmaceuticals, Inc. Furthermore, he has experience as an Assistant Professor at Washington University School of Medicine.
Dr. Levisetti obtained his doctorate degree from Pritzker School of Medicine in 1996.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CUE BIOPHARMA, INC.
0.02% | 06-03-2024 | 9 230 ( 0.02% ) | 17 445 $ | 31-03-2024 |
Actieve functies van Matteo Levisetti
| Bedrijven | Functie | Begin |
|---|---|---|
| CUE BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 22-02-2021 |
Eerdere bekende functies van Matteo Levisetti
| Bedrijven | Functie | Einde |
|---|---|---|
DNAtrix, Inc.
 DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Chief Tech/Sci/R&D Officer | 01-01-2021 |
Dauntless Pharmaceuticals, Inc.
 Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01-06-2018 |
| MIRATI THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01-05-2017 |
| Washington University School of Medicine | Corporate Officer/Principal | - |
Roche Pharmaceuticals, Inc.
 Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Corporate Officer/Principal | - |
Opleiding van Matteo Levisetti
| Pritzker School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CUE BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Roche Pharmaceuticals, Inc.
Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ. | Commercial Services |
DNAtrix, Inc.
DNAtrix, Inc. Electronic Equipment/InstrumentsElectronic Technology DNAtrix, Inc. operates as a biotech company which focuses on the development of oncolytic viruses for cancer. The firm’s offers DNX-2401 product which is an oncolytic virus designed specifically for treating Glioblastoma. It also works to expand its platform technology for treating other cancers, including ovarian, prostate and pancreatic cancer indications. The company was founded in 2005 by Francis Patrick McCormick, Alfred Yung, Charles Conrad, Cande Gomez-Manzano and Juan Fueyo and is headquartered in Houston, TX. | Electronic Technology |
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Dauntless Pharmaceuticals, Inc.
Dauntless Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA. | Retail Trade |
